▎藥明康德

上海，2025年7月11日，為全球醫藥及生命科學行業提供全方位、一體化新藥研發和生產服務的能力和技術平臺公司——無錫藥明康德新藥開發股份有限公司（股票代碼：603259.SH/2359.HK）發布2025年半年度業績預增公告，并披露主要經營數據預測。

公告重要提示如下：

藥明康德持續聚焦獨特的“一體化、端到端”CRDMO業務模式，緊抓客戶對賦能需求的確定性，不斷拓展新能力、建設新產能，持續優化生產工藝和提高經營效率，推動業務持續穩健增長，高效極致賦能客戶并致力于將更多新藥、好藥帶給全球病患。

• 營業收入：預計2025年上半年實現約人民幣208.0億元，同比增長約20.6%，其中持續經營業務收入同比增長約24.2%。

• 經調整Non-IFRS歸母凈利潤：預計2025年上半年實現約人民幣63.1億元，同比增長約44.4%。

• 扣非歸母凈利潤：預計2025年上半年實現約人民幣55.8億元，同比增長約26.5%，與經調整Non-IFRS歸母凈利潤增速相比主要受到匯率波動的影響。

• 歸母凈利潤：預計2025年上半年實現約人民幣85.6億元，同比增長約101.9%，其中包含了出售聯營公司部分股權所獲得的投資收益；預計2025年上半年基本每股收益約人民幣3.01元/股，同比增長約106.2%。

藥明康德將在2025年7月29日發布2025年上半年業績時提供更多詳細信息。

更多信息，請見公司相關公告：2025年半年度業績預增公告。

掃碼查看公告

關于藥明康德

藥明康德（股票代碼：603259.SH/2359.HK）是全球醫藥及生命科學行業值得信賴的合作伙伴和重要貢獻者，致力于通過提供一體化、端到端的新藥研發和生產服務，推動全球醫藥健康創新。公司在亞洲、歐洲、北美等地均設有運營基地，依托獨特的“CRDMO”業務模式，不斷降低研發門檻，助力客戶提升研發效率，為患者帶來突破性的治療方案。目前，公司的賦能平臺正承載著來自全球30多個國家的約6,000家合作伙伴的研發創新項目，致力于將更多新藥、好藥帶給全球病患，早日實現“讓天下沒有難做的藥，難治的病”的愿景。更多信息，請訪問公司網站：www.wuxiapptec.com

WuXi AppTec Issues Positive Profit Alert for the First Half of 2025

Shanghai, July 11, 2025 – WuXi AppTec Co., Ltd. (stock code: 603259.SH/2359.HK), a leading global pharmaceutical and life sciences technology platform company offering integrated, end-to-end new drug R&D and manufacturing services, has issued a Positive Profit Alert for the first half of 2025 and disclosed key operational data forecasts.

Important notice of the announcement are as follows:

WuXi AppTec maintains a laser focus on the Company’s unique, integrated and end-to-end CRDMO (Contract Research, Development and Manufacturing Organization) business model. In response to customers’ ongoing demand for enabling services, the Company continues to enhance its capabilities and capacity, optimize production processes and improve operating efficiency. These factors are driving sustained long-term business growth, delivering highly efficient and exceptional services to customers and helping to bring groundbreaking therapies to patients worldwide.

• Total revenuefor the first half of 2025 is expected to be approximately RMB20.80 billion, representing a year-over-year increase of approximately 20.6%, with revenue from Continuing Operations growing by approximately 24.2% year-over-year.

• Adjusted non-IFRS net profitfor the first half of 2025 is expected to be approximately RMB6.31 billion, representing a year-over-year increase of approximately 44.4%.

• Net profit after deducting non-recurring items1for the first half of 2025 is expected to be approximately RMB5.58 billion, representing a year-over-year increase of approximately 26.5%. The growth rate compared to the adjusted non-IFRS net profit is mainly affected by exchange rate fluctuations.

• Net profit attributable to the owners of the Company1for the first half of 2025 is expected to be approximately RMB8.56 billion, representing a year-over-year increase of approximately 101.9%, which includes the gain on partial disposal of associates. Basic earnings per share for the first half of 2025 is expected to be approximately RMB3.01, representing a year-over-year increase of approximately 106.2%.

WuXi AppTec will provide additional details when the Company releases its results for the first half of 2025 on July 29, 2025.

For more information, please refer to the Company's related announcements: Positive Profit Alert.

Scan the QR code to view the announcement

[1] Net profit after deducting non-recurring items and net profit attributable to the owners of the Company are both prepared in accordance with China Accounting Standards for Business Enterprises (CAS).

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer an integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside nearly 6,000 partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at www.wuxiapptec.com.

免責聲明：本文僅作信息交流之目的，文中觀點不代表藥明康德立場，亦不代表藥明康德支持或反對文中觀點。本文也不是治療方案推薦。如需獲得治療方案指導，請前往正規醫院就診。

版權說明：歡迎個人轉發至朋友圈，謝絕媒體或機構未經授權以任何形式轉載至其他平臺。轉載授權請在「藥明康德」微信公眾號回復“轉載”，獲取轉載須知。